FAQ: Soligenix's SGX302 Psoriasis Treatment and Company Overview
TL;DR
Soligenix's SGX302 offers investors exposure to a $67 billion psoriasis market opportunity with promising phase 2a clinical trial results.
Soligenix is conducting a phase 2a clinical trial of SGX302, a synthetic hypericin therapy that shows safety and biological activity for psoriasis treatment.
Soligenix's psoriasis treatment development could provide millions of patients with a novel, well-tolerated therapy for this chronic autoimmune skin condition.
Soligenix leverages synthetic hypericin technology originally developed for cancer treatment to address psoriasis in a novel photodynamic therapy approach.
Found this article helpful?
Share it with your network and spread the knowledge!
SGX302 is a synthetic hypericin therapy being developed by Soligenix for the treatment of mild-to-moderate psoriasis, a chronic autoimmune skin condition affecting millions globally.
SGX302 is currently in phase 2a clinical trials, building on promising phase 1/2 data that showed encouraging signs of safety and biological activity.
SGX302 represents a novel, well-tolerated treatment option for psoriasis and addresses a significant market opportunity projected to reach $67 billion by 2030.
Soligenix is also developing HyBryte™ (SGX301), a synthetic hypericin photodynamic therapy using safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), which has completed its second Phase 3 study.
Soligenix has development programs including dusquetide (SGX942) for inflammatory diseases like oral mucositis, SGX945 for Behçet's disease, and vaccine programs for ricin toxin, filoviruses (Marburg and Ebola), and COVID-19 (CiVax™).
Soligenix's vaccine programs have been supported with government grants and contract funding from NIAID, DTRA, and BARDA, and incorporate the company's proprietary heat stabilization platform technology called ThermoVax®.
The latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX.
Successful ongoing trial results could pave the way for larger studies, regulatory guidance, and eventual commercialization of SGX302 for psoriasis treatment.
For further information, visit the company's website at www.Soligenix.com.
Curated from InvestorBrandNetwork (IBN)
